Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 3, 2007, Pages 556-559

  Ghannoum, Mahmoud A ^a   Kim, H G ^a   Long, L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Candida albicans; Echinocandins; In vivo

Indexed keywords

AMINOCANDIN; AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; NONHUMAN; SURVIVAL RATE; TISSUE LEVEL; ANIMAL; ANTIBIOTIC RESISTANCE; BAGG ALBINO MOUSE; FUNGEMIA; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; LIPOPROTEINS; MICE; MICE, INBRED BALB C;

EID: 34248170227     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl525     Document Type: Article

References (10)

1. Hiller D, Stahl S, Morschhauser J. Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate. Antimicrob Agents Chemother 2006; 50: 1664-9.
2. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-86.
3. Myoken Y, Kyo T, Sugata T et al. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. Haematologica 2006; 91: 287-8.
4. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
5. Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006; 11 231-50.
6. Warn PA, Sharp A, Morrissey G et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 2005; 56 590-3.
7. Steinbach WJ, Schell WA, Blankenship JR et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004; 48: 1664-9.
8. Hossain MA, Reyes GH, Long LA et al. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51: 1427-9.
9. Hossain MA, Maesaki S, Razzaque MS et al. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B. J Antimicrob Chemother 2000; 46: 263-8.
10. Andes D, Marchillo K, Lowther J et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-92.